In this review, we summarize ADs that are associated with malignant melanoma, we explore how STAT3 and STAT5 signaling contributes to their pathogenesis, and we evaluate STAT3/STAT5 inhibition as a feasible strategy to target these diseases in order to achieve their simultaneous management with a single drug. The gene discussed is STAT5B; the disease is melanoma.